Men with prostate cancer avoid radiation due to misconceptions

November 05, 2006

Negative perceptions about radiation therapy can strongly influence a prostate cancer patient's choice to avoid external beam radiation therapy, even though studies have proven the treatment to be as safe and effective as other treatments for the disease, including surgery, according to a study presented November 5, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.

"The study shows that patients base their treatment choice not only on technical information, but also on cultural and personal prejudices," said Riccardo Valdagni, M.D., an author of the study and head of the Prostate Programme at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. "It's important for patients to express their fears about radiation treatment to their doctors and for doctors to consider these worries and address any misconceptions about this therapy so that patients can make the best, most informed decision about their treatment."

Men with prostate cancer often choose between external beam radiation therapy, radiation seed implants and surgery to treat their cancer. During external beam radiation, a beam of radiation, or X-ray, is directed through the skin to the cancer and the immediate surrounding area to kill the cancer. To minimize side effects, radiation is given five days a week for several weeks. Many men with prostate cancer choose external beam radiation over other treatments because it is non-invasive, has a short recovery period and often helps men preserve their sexual and urinary function.

However, Dr. Valdagni's study shows that some men with prostate cancer have definite fears about radiation treatment, with the greatest worries related to false beliefs on how the X-rays would affect them. For example, some patients think that radiation cannot be controlled because it is invisible, that it will harm surrounding unprotected organs and that it is dangerous for family members to physically be near them when undergoing radiation treatment. Patients also said that the terminology used in radiation therapy, such as the term "hitting the target," evoked feelings more related to war than to a cure. In addition, while some patients experienced technology as reassuring, many others felt that the technologically advanced computer equipment used during radiation treatment provoked anxiety.

The study was carried out by a multidisciplinary team of doctors (urologists, radiation oncologists, medical oncologists and psychologists) at the Milan National Cancer Institute Prostate Cancer Program from March 2005 to March 2006. The team interviewed 257 men with prostate cancer to find out their perceptions about radiation therapy.
-end-
For more information on radiation therapy for prostate cancer, visit www.rtanswers.org.

The abstract, "Patient's Fantasies and Worries about Radiation Therapy for Prostate Cancer during the Decision Making Phase," will be presented on Sunday, November 5, at 12:00 p.m. To speak to the author of the study, Riccardo Valdagni, M.D., please call Beth Bukata or Julie Moore November 5-8 in the ASTRO Press Room at the Pennsylvania Convention Center at 215-418-2257 or 215-418-2258. You may also e-mail Julie at juliem@astro.org.

American Society for Radiation Oncology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.